Shots:
- The first patient has been dosed in a P-I CIBI323A101 study evaluating IBI323 (anti-LAG-3/PD-L1 bispecific Ab) in patients with advanced solid tumors. The trial is being conducted in China
- The purpose of the P-I dose-escalation and expansion study is to evaluate the safety, tolerability, optimal dosage, and preliminary efficacy of IBI323 in patients with advanced malignant tumors whose cancer progressed on SoC treatment
- The preclinical studies showed that IBI323 effectively blocks both the PD-1/PD-L1 and LAG-3 pathways and enhance the T lymphocyte activation compared with the combination of anti-PD-L1 and anti-LAG mAb
Click here to read full press release/ article | Ref: PR Newswire | Image: Innovent
The post Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors first appeared on PharmaShots.
